The United States is no stranger to drug epidemics. Whether you examine the start of amphetamine abuse in the 1950s and the rise of heroin addiction in the ’60s or look at just how quickly cocaine and crack took hold of the U.S. in the ’80s and ’90s, there’s no question that these epidemics come in waves.
Today, you’d be hard-pressed to find anyone in law enforcement who isn’t challenged by the latest surge of drug activity, either in the form of xylazine or fentanyl abuse. Opioids disguised as prescription pills have proliferated every corner of the U.S. and were responsible for 75% of all overdose deaths in 2021 alone.
Just when it seems the country is at its breaking point with these drugs, another narcotic is taking hold of users across the world, one which might very soon make its way stateside. While its manufacture and distribution has largely been contained to countries in the Middle East, it is now infiltrating Europe and could already have its sights set on its next target demographic – the United States.
Download this white paper to learn:
- What’s fueling the global resurgence of this drug.
- How to identify if a suspect is under the influence of Captagon.
- Ways your agency can prepare for this potential new epidemic.
